Table 4.
Efficacy of FDA Approved Vaccines Against Selected Sars-Cov2 Variants (Gubbay et al., 2021).
|
Virus variant | |||
|---|---|---|---|
| Name of the vaccine | Alpha Variant (B.1.1.7) | Beta Variant (B.1.351) | Delta Variant (B.1.617.2) |
| Comirnaty (Pfizer BioNTech) | Vaccine effectiveness Vs symptomatic infection | Vaccine effectiveness Vs symptomatic infection | Vaccine effectiveness Vs symptomatic infection |
| Dose 1 | 95 % CI 64–68 % | 95 % CI 52–67 % | ∼56 % |
| Dose 2 | 95 % CI 86–91 % | 95 % CI 69–92 % | 95 % CI 64–95 % |
| Spikevax (Moderna) | Vaccine effectiveness Vs Hospitalization rate | Vaccine effectiveness Vs Hospitalization rate | Vaccine effectiveness Vs Hospitalization rate |
| Dose 1 | 95 % CI 80–86 % | 95 % CI 69–92 % | ∼78 % |
| Dose 2 | 95 % CI 86–96 % | No information | No information |
| Janssen COVID-19 Vaccine (Johnson & Johnson) | Vaccine effectiveness Vs symptomatic infection rate | Vaccine effectiveness Vs symptomatic infection rate | Vaccine effectiveness Vs symptomatic infection rate |
| Dose 1 | effective according to the manufacturer | effective according to the manufacturer | effective according to the manufacturer |
Legend: 95 % CI – 95 % confidence interval.